TherapeuticsMD (TXMD) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 04, 2014
Document And Entity Information	'	'
Entity Registrant Name	'TherapeuticsMD, Inc.	'
Entity Central Index Key	'0000025743	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	155,807,765
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash	$35,553,836	$54,191,260
Accounts receivable, net of allowance for doubtful accounts of $27,948 and $26,555, respectively	2,164,738	1,690,753
Inventory	1,452,994	1,043,618
Other current assets	2,678,200	2,477,715
Total current assets	41,849,768	59,403,346
Fixed assets, net	76,689	61,318
Other Assets:	'	'
Prepaid expense	1,511,549	1,750,455
Intangible assets	867,107	665,588
Security deposit	125,000	135,686
Total other assets	2,503,656	2,551,729
Total assets	44,430,113	62,016,393
Current Liabilities:	'	'
Accounts payable	2,330,257	2,114,217
Deferred revenue	1,287,796	1,602,580
Other current liabilities	3,329,418	3,601,189
Total current liabilities	6,947,471	7,317,986
Total liabilities	6,947,471	7,317,986
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding	'	'
Common stock - par value $0.001; 250,000,000 shares authorized; 145,926,973 and 144,976,757 issued and outstanding, respectively	145,927	144,977
Additional paid in capital	137,951,719	135,086,056
Accumulated deficit	-100,615,004	-80,532,626
Total stockholders' equity	37,482,642	54,698,407
Total liabilities and stockholders' equity	$44,430,113	$62,016,393

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$32,601	$26,555
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	145,926,973	144,976,757
Common stock, shares outstanding	145,926,973	144,976,757

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenues, net	$3,751,778	$2,080,885	$6,582,311	$3,618,080
Cost of goods sold	892,956	463,606	1,723,663	843,952
Gross profit	2,858,822	1,617,279	4,858,648	2,774,128
Operating expenses:	'	'	'	'
Sales, general, and administrative	5,537,164	5,476,553	10,566,661	10,003,135
Research and development	8,234,641	1,747,084	14,142,719	3,312,285
Depreciation and amortization	14,094	10,636	27,162	18,593
Total operating expense	13,785,899	7,234,273	24,736,542	13,334,013
Operating loss	-10,927,077	-5,616,994	-19,877,894	-10,559,885
Other income and (expense)	'	'	'	'
Miscellaneous income	18,579	3,479	37,151	3,479
Interest income	9,238	'	18,392	'
Interest expense	'	-150	'	-1,165,981
Financing costs	'	-395,981	-260,027	-659,968
Loan guaranty costs	'	'	'	-2,944
Total other expense	27,817	-392,652	-204,484	-1,825,414
Loss before taxes	-10,899,260	-6,009,646	-20,082,378	-12,385,299
Net loss	($10,899,260)	($6,009,646)	($20,082,378)	($12,385,299)
Net loss per share, basic and diluted	($0.07)	($0.05)	($0.14)	($0.11)
Weighted average number of shares outstanding	145,485,505	130,851,978	145,253,818	116,866,764

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($20,082,378)	($12,385,299)
Adjustments to reconcile net loss to net cash flows used in operating activities:	'	'
Depreciation	15,591	12,084
Amortization of intangible assets	11,570	6,509
Provision for doubtful accounts	1,393	58,337
Stock based compensation	2,268,599	1,179,912
Stock based expense for services	481,024	637,155
Amortization of deferred financing costs	260,027	659,938
Amortization of debt discount	'	1,102,680
Loan guaranty costs	'	2,944
Changes in operating assets and liabilities:	'	'
Accounts receivable	-475,378	-409,475
Inventory	-409,376	109,151
Other current assets	-460,512	-1,696,551
Other assets	-18,392	-899,000
Accounts payable	216,040	403,750
Deferred revenue	-314,784	74,320
Accrued expenses and other current liabilities	-271,771	458,792
Net cash flows used in operating activities	-18,778,347	-10,684,753
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Patent costs, net of abandoned costs	-213,089	-112,192
Purchase of property and equipment	-30,962	-22,905
Refund (payment) of security deposit	10,686	-125,000
Net cash flows used in investing activities	-233,365	-260,097
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from exercise of options	287,288	6,231
Proceeds from exercise of warrants	87,000	'
Proceeds from sale of common stock, net	'	48,512,460
Proceeds from line of credit	'	500,000
Repayment of line of credit	'	-500,000
Repayment of notes payable	'	-4,691,847
Net cash flows provided by financing activities	374,288	43,826,844
(Decrease) increase in cash	-18,637,424	32,881,994
Cash, beginning of period	54,191,260	1,553,474
Cash, end of period	35,553,836	34,435,468
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'
Cash paid for interest	'	212,853
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:	'	'
Warrants issued for financing	'	1,711,956
Warrants issued for services	'	$462,196

THE_COMPANY

THE COMPANY	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
THE COMPANY	'
	NOTE 1 – THE COMPANY
	TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”
	Nature of Business
	We are a women’s health care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins and cosmetics.

BASIS_OF_PRESENTATION_AND_RECE

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	'
	NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	Interim Financial Statements
	The accompanying unaudited interim condensed consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission, or the SEC, from which we derived our balance sheet as of December 31, 2013. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
	Recently Issued and Newly Adopted Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) and the International Accounting Standards Board (IASB) issued Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on our financial statements and disclosures.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have a material impact on our condensed consolidated financial statements.
	In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or results of operations.
	We do not believe there would have been a material effect on the accompanying condensed consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.
	Reclassifications
	Certain 2013 amounts have been reclassified to conform to current year presentation.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2013.
	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		·	significant declines in an asset’s market price;
		·	significant deterioration in an asset’s physical condition;
		·	significant changes in the nature or extent of an asset’s use or operation;
		·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets during the three or six months ended June 30, 2014 and 2013.
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At June 30, 2014 and December 31, 2013, we had no assets or liabilities that were valued at fair value on a recurring basis.

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
INVENTORY	'
	NOTE 4 – INVENTORY
	Inventory consists of the following:
		June 30,		December 31,
		2014		2013
	Finished product	$	747,001	$	621,679
	Raw material		518,701		250,943
	Deferred costs		187,292		170,996
	TOTAL INVENTORY	$	1,452,994	$	1,043,618

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	6 Months Ended
	Jun. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
OTHER CURRENT ASSETS	'
	NOTE 5 – OTHER CURRENT ASSETS
	Other current assets consist of the following:
		June 30,		December 31,
		2014		2013
	Prepaid research and development costs	$	1,663,147	$	1,267,588
	Prepaid consulting		514,596		530,596
	Other receivables-related party (Note 14)		249,981		249,981
	Prepaid insurance		174,917		125,266
	Other prepaid costs		75,559		44,262
	Deferred financing costs		—		260,022
	TOTAL OTHER CURRENT ASSETS	$	2,678,200	$	2,477,715

FIXED_ASSETS

FIXED ASSETS	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
FIXED ASSETS	'
	NOTE 6 – FIXED ASSETS
	Fixed assets consist of the following:
		June 30,			December 31,
		2014			2013
	Equipment	$	132,150		$	108,458
	Furniture and fixtures		53,895			46,625
			186,045			155,083
	Accumulated depreciation		(109,356	)		(93,765	)
	TOTAL FIXED ASSETS	$	76,689		$	61,318
	Depreciation expense for the three months ended June 30, 2014 and 2013 was $8,469 and $7,381, respectively. Depreciation expense for the six months ended June 30, 2014 and 2013 was $15,591 and $12,084 respectively.

PREPAID_EXPENSE

PREPAID EXPENSE	6 Months Ended
	Jun. 30, 2014
Prepaid Expense and Other Assets [Abstract]	'
PREPAID EXPENSE	'
	NOTE 7 – PREPAID EXPENSE
	Prepaid expense consisted of the following:
		June 30,		December 31,
		2014		2013
	Prepaid research and development costs	$	566,923	$	824,221
	Prepaid manufacturing costs		899,000		899,000
	Accreted prepaid costs		45,626		27,234
	TOTAL PREPAID EXPENSE	$	1,511,549	$	1,750,455

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 8 – INTANGIBLE ASSETS
	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2014 and December 31, 2013:
		30-Jun-14
		Gross Carrying Amount		Accumulated Amortization			Net		Weighted- Average Remaining Amortization Period (yrs.)
							Amount
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(1,498	)	$	30,453		15.25
	Development costs of corporate website		91,743		(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents		387,806		(8,489	)		379,317		18.75
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)		381,369		—			381,369		n/a
	Multiple trademarks for vitamins/supplements		75,968		—			75,968		n/a
	Total	$	968,837	$	(101,730	)	$	867,107
		31-Dec-13
		Gross Carrying Amount		Accumulated Amortization			Net		Weighted- Average Remaining Amortization Period (yrs.)
							Amount
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
	Development costs of corporate website		91,743		(89,661	)		2,082		0.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)		572,726		—			572,726		n/a
	Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
	Total	$	755,748	$	(90,160	)	$	665,588
	We amortize the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software and website development costs. We amortize the intangible asset related to OPERA® using the straight-line method over the estimated useful life of approximately 20 years, which is the life of the intellectual property patents. We amortize the approved hormone therapy drug candidate patents using straight-line method over the estimated useful life of approximately 20 years. During the three and six months ended June 30, 2014 and 2013, there was no impairment recognized.
	Amortization expense was $5,625 and $3,255 for the three months ended June 30, 2014 and 2013, respectively and $11,570 and $6,509 for the six months ended June 30, 2014 and 2013, respectively. Estimated amortization expense for the next five years is as follows:
	Year Ending	Estimated
	December 31,	Amortization
	2014 (6 months)	$	11,250
	2015	$	22,500
	2016	$	22,500
	2017	$	22,500
	2018	$	22,500

OTHER_CURRENT_LIABILITIES

OTHER CURRENT LIABILITIES	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
OTHER CURRENT LIABILITIES	'
	NOTE 9 – OTHER CURRENT LIABILITIES
	Other current liabilities consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued payroll and commission costs	$	1,207,486	$	941,313
	Accrued clinical trial costs		725,723		129,208
	Accrued vacation costs		406,597		256,920
	Allowance for wholesale distributor fees		273,026		306,303
	Accrued legal and accounting expense		192,972		224,550
	Accrued royalties		155,221		52,188
	Allowance for coupons and returns		107,007		126,233
	Accrued rent		94,435		—
	Other accrued expenses(1)		166,951		177,900
	Accrued financing costs		—		850,000
	Accrued lab research		—		536,574
	TOTAL OTHER CURRENT LIABILITIES	$	3,329,418	$	3,601,189
	_____________________
	(1) In June 2008, we declared and paid a special dividend of $0.40 per share of our common stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2014 and December 31, 2013.

NOTES_PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
NOTES PAYABLE	'
	NOTE 10 – NOTES PAYABLE
	Issuance and Payment of Multiple Advance Revolving Credit Note
	On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request, which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our common stock at an exercise price of $3.20 per share (See Note 12).

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
NET LOSS PER SHARE	'
	NOTE 11 – NET LOSS PER SHARE
	We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our common stock outstanding subject to repurchase or forfeiture for the three or six months ended June 30, 2014 and 2013, respectively.
	Since we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as warrants for the purchase of our common stock from our calculation of diluted net loss per share.
	The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.
		Three months ended
		June 30,		June 30,
		2014		2013
	Stock options		16,523,128		14,655,793
	Warrants		14,122,127		14,293,499
			30,645,255		28,949,292

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 12 – STOCKHOLDERS’ EQUITY
	Preferred Stock
	June 30, 2014, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.
	Common Stock
	At June 30, 2014, we had 250,000,000 shares of common stock, $0.001 par value per share, authorized, of which 145,926,973 shares of common stock were issued and outstanding.
	Issuances During the Six Months Ended June 30, 2014
	During the six months ended June 30, 2014, certain individuals exercised stock options to purchase 728,844 shares of our common stock. Stock options to purchase shares of our common stock were exercised as follows: (i) 615,007 options for $287,288 in cash and (ii) 119,607 options, pursuant to the stock options’ cashless provision, wherein 113,837 common shares were issued. The Company granted 50,000 common shares to an employee upon the vesting of restricted stock units which were granted in December 2013.
	During the six months ended June 30, 2014, certain individuals exercised warrants to purchase 171,372 shares of our common stock for $87,000 in cash.
	Issuances During the Year Ended December 31, 2013
	On March 14, 2013, we entered into an underwriting agreement with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our common stock. The price to the public in the offering was $1.70 per share, and the Jefferies Underwriters agreed to purchase the shares of our common stock from us pursuant to the underwriting agreement at a price of $1.58 per share. The net proceeds to us from this offering were approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our common stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our common stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.
	On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated, as the representative of the underwriters named therein, or the Stifel Underwriters, relating to the issuance and sale of 13,750,000 shares of our common stock. The price to the public in the offering was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our common stock from us pursuant to the underwriting agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.
	During 2013 certain individuals exercised their right to purchase shares of our common stock. Stock options to purchase an aggregate of 75,423 shares of our common stock were exercised for approximately $31,000.
	Warrants to Purchase Common Stock of the Company
	As of June 30, 2014, we had warrants outstanding to purchase an aggregate of 14,122,127 shares of our common stock with a weighted-average contractual remaining life of 3.5 years, and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.80 per share.
	The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.
	Warrant Activity During the Six Months Ended June 30, 2014
	During the six months ended June 30, 2014, we did not grant any warrants.
	Warrant Activity During the Year Ended December 31, 2013
	In January 2013, we granted warrants to purchase 1,250,000 shares of our common stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE 10 for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the six months ended June 30, 2014, $260,027 was recorded as financing costs in connection with issuance of Plato Warrant on the accompanying condensed consolidated financial statements. For the three and six months ended June 30, 2013, $395,981 and $659,968, respectively was recorded as financing costs in connection with issuance of Plato Warrant on the accompanying condensed consolidated financial statements.
	In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our common stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of our common stock at $2.01 per share that has vested or will vest, as applicable, as follows:
		1	283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;
		2	283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $192,577 as prepaid expense-long term in the accompanying condensed consolidated financial statements. During the three and six months ended June 30, 2014, we recorded $38,517 and $77,034 as non-cash compensation in the accompanying condensed consolidated financial statements; and
		3	283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2015.
	As of June 30, 2014, unamortized costs associated with the warrants totaled approximately $1.1 million.
	Stock Options to Purchase Common Stock of the Company
	On September 25, 2009, our board of directors approved the 2009 Long Term Incentive Compensation Plan, or the LTIP, to provide financial incentives to our employees, members of the board of directors, and our advisers and consultants who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other equity and cash incentives, or the Awards.
	The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP. There are 25,000,000 shares authorized for issuance under the LTIP. Under the LTIP, non-qualified stock options for the purchase of an aggregate of 14,554,654 shares of our common stock were outstanding at June 30, 2014.
	On February 23, 2012, our board of directors approved the 2012 Stock Incentive Plan, and on June 10, 2013, approved the Amended and Restated 2012 Stock Incentive Plan, or the 2012 SOP. The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors. There are 10,000,000 shares authorized for issuance under the 2012 SOP. Non-qualified stock options for the purchase of an aggregate of 1,968,474 shares of our common stock were outstanding as of June 30, 2014.
	The valuation methodology used to determine the fair value of the stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the six months ended June 31, 2014 and year ended December 31, 2013 are set forth in the table below.
			Six Months Ended June 30, 2014			Six Months Ended June 30, 2013
	Risk-free interest rate			1.70-1.77	%		0.65-1.42	%
	Volatility			69.15-70.93	%		33.35-45.76	%
	Term (in years)			5-6.25			5-6.25
	Dividend yield			0	%		0	%
	The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual term of the stock option using the simplified method.
	A summary of activity under the LTIP and 2012 SOP and related information follows:
			Number of Shares Underlying Stock Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
	Balance at December 31, 2013			15,632,742		$	1.44			7.2	$	58,878,132
	Granted			1,625,000		$	4.82			9.7	$	162,000
	Exercised			(728,844	)
	Expired			—
	Cancelled			(5,770	)
	Balance at June 30, 2014			16,523,128		$	1.82			7.3	$	43,880,788
	Vested and Exercisable at June 30, 2014			11,958,967		$	1.17			6.1	$	38,859,553
	The Black-Scholes Model is used to calculate the fair value of individual stock option grants on their issue date. The weighted-average issue date fair value of stock options issued during the six months ended June 30, 2014 was $2.99. Stock options issued under our plan and outstanding exercise prices range from $0.10 to $5.21 per share. Stock-based compensation expense for stock options recognized in our results of operations for the three and six months ended June 30, 2014 were $1,250,002 and $2,070,385, respectively, and $561,810 and $1,161,770, respectively for the same periods in 2013 (all based on awards vested and was estimated without forfeitures). Stock-based expense for services for stock options recognized in our results of operations for the three and six months ended June 30, 2014 were $38,084 and $223,726, respectively, and $7,477 for both of the same periods in 2013 (all based on awards vested and was estimated without forfeitures). ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At June 30, 2014, total unrecognized estimated compensation expense related to unvested stock options previously issued was approximately $6,621,000, which is expected to be recognized over a weighted-average period of 2.1 years. No tax benefit was realized due to a continued pattern of operating losses.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 13 – INCOME TAXES
	Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2014 as a result of (i) the losses recorded during the six months ended June 30, 2014, (ii) additional losses expected for the remainder of 2014, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2014, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

RELATED_PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	NOTE 14 – RELATED PARTIES
	On February 29, 2012, Cooper C. Collins, who was then the largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. On October 5, 2011, we closed a stock purchase agreement with Pernix. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors. During the six months ended June 30, 2014 and 2013, we did not engage in any transactions with Pernix. At June 30, 2014 and December 31, 2013, there were amounts due Pernix of approximately $46,000.
	Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and supply agreement in the amounts of $249,981 at both June 30, 2014 and December 31, 2013.

BUSINESS_CONCENTRATIONS

BUSINESS CONCENTRATIONS	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
BUSINESS CONCENTRATIONS	'
	NOTE 15 - BUSINESS CONCENTRATIONS
	We purchase our products from several suppliers with approximately 71% and 98% of our purchases supplied from one vendor for the six months ended June 30, 2014 and 2013, respectively.
	We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from four major customers accounted for 97.17% and 98.16% of our recognized revenue for the six months ended June 30, 2014 and 2013, respectively.
	For the six months ended June 30, 2014 and 2013, 81.65% and 74.08% of our recognized revenue and 95.20% and 97.94% of our deferred revenue was generated from sales to four major customers.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 16 – COMMITMENTS AND CONTINGENCIES
	We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.
	The straight line rental expense related to our current lease totaled $90,448 and $180,896 for the three and six months periods ended June 30, 2014 offset by rent income of $35,960. The rental expense related to our prior lease, which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013.
	As of June 30, 2014, future minimum rental payments are as follows:
	Years Ending
	December 31,
	2014 (6 months)	$	182,877
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,748
	Total minimum lease payments	$	1,633,090

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 17 – SUBSEQUENT EVENTS
	Public Offering of Stock
	On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs & Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to the issuance and sale of 8,565,310 shares of our common stock. The price to the public in the offering was $4.67 per share, and the Goldman Sachs Underwriters agreed to purchase the shares of our common stock from us pursuant to the underwriting agreement at a price of approximately $4.37 per share. The net proceeds to us from this offering were approximately $37.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of our common stock. The offering closed on August 4, 2014. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase an additional 1,284,796 shares of our common stock. We issued these shares to the Goldman Sachs Underwriters at the closing on August 4, 2014 and received additional proceeds of approximately $5.6 million, net of expenses.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		·	significant declines in an asset’s market price;
		·	significant deterioration in an asset’s physical condition;
		·	significant changes in the nature or extent of an asset’s use or operation;
		·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets during the three or six months ended June 30, 2014 and 2013.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At June 30, 2014 and December 31, 2013, we had no assets or liabilities that were valued at fair value on a recurring basis.

INVENTORY_Tables

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following:
		June 30,		December 31,
		2014		2013
	Finished product	$	747,001	$	621,679
	Raw material		518,701		250,943
	Deferred costs		187,292		170,996
	TOTAL INVENTORY	$	1,452,994	$	1,043,618

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	6 Months Ended
	Jun. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of other current assets	'
	Other current assets consist of the following:
		June 30,		December 31,
		2014		2013
	Prepaid research and development costs	$	1,663,147	$	1,267,588
	Prepaid consulting		514,596		530,596
	Other receivables-related party (Note 14)		249,981		249,981
	Prepaid insurance		174,917		125,266
	Other prepaid costs		75,559		44,262
	Deferred financing costs		—		260,022
	TOTAL OTHER CURRENT ASSETS	$	2,678,200	$	2,477,715

FIXED_ASSETS_Tables

FIXED ASSETS (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of fixed assets	'
	Fixed assets consist of the following:
		June 30,			December 31,
		2014			2013
	Equipment	$	132,150		$	108,458
	Furniture and fixtures		53,895			46,625
			186,045			155,083
	Accumulated depreciation		(109,356	)		(93,765	)
	TOTAL FIXED ASSETS	$	76,689		$	61,318

PREPAID_EXPENSE_Tables

PREPAID EXPENSE (Tables)	6 Months Ended
	Jun. 30, 2014
Prepaid Expense and Other Assets [Abstract]	'
Schedule of prepaid expense	'
	Prepaid expense consisted of the following:
		June 30,		December 31,
		2014		2013
	Prepaid research and development costs	$	566,923	$	824,221
	Prepaid manufacturing costs		899,000		899,000
	Accreted prepaid costs		45,626		27,234
	TOTAL PREPAID EXPENSE	$	1,511,549	$	1,750,455

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of intangible assets	'
	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2014 and December 31, 2013:
		30-Jun-14
		Gross Carrying Amount		Accumulated Amortization			Net		Weighted- Average Remaining Amortization Period (yrs.)
							Amount
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(1,498	)	$	30,453		15.25
	Development costs of corporate website		91,743		(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents		387,806		(8,489	)		379,317		18.75
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)		381,369		—			381,369		n/a
	Multiple trademarks for vitamins/supplements		75,968		—			75,968		n/a
	Total	$	968,837	$	(101,730	)	$	867,107
		31-Dec-13
		Gross Carrying Amount		Accumulated Amortization			Net		Weighted- Average Remaining Amortization Period (yrs.)
							Amount
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
	Development costs of corporate website		91,743		(89,661	)		2,082		0.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)		572,726		—			572,726		n/a
	Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
	Total	$	755,748	$	(90,160	)	$	665,588
Schedule of estimated amortization expense	'
	Estimated amortization expense for the next five years is as follows:
	Year Ending	Estimated
	December 31,	Amortization
	2014 (6 months)	$	11,250
	2015	$	22,500
	2016	$	22,500
	2017	$	22,500
	2018	$	22,500

OTHER_CURRENT_LIABILITIES_Tabl

OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Schedule of other current liabilities	'
	Other current liabilities consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued payroll and commission costs	$	1,207,486	$	941,313
	Accrued clinical trial costs		725,723		129,208
	Accrued vacation costs		406,597		256,920
	Allowance for wholesale distributor fees		273,026		306,303
	Accrued legal and accounting expense		192,972		224,550
	Accrued royalties		155,221		52,188
	Allowance for coupons and returns		107,007		126,233
	Accrued rent		94,435		—
	Other accrued expenses(1)		166,951		177,900
	Accrued financing costs		—		850,000
	Accrued lab research		—		536,574
	TOTAL OTHER CURRENT LIABILITIES	$	3,329,418	$	3,601,189
	_____________________
	(1) In June 2008, we declared and paid a special dividend of $0.40 per share of our common stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2014 and December 31, 2013.

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of potentially dilutive securities	'
	The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.
		Three months ended
		June 30,		June 30,
		2014		2013
	Stock options		16,523,128		14,655,793
	Warrants		14,122,127		14,293,499
			30,645,255		28,949,292

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of assumptions used in the Black-Scholes Model of stock options	'
	The assumptions used in the Black-Scholes Model during the six months ended June 31, 2014 and year ended December 31, 2013 are set forth in the table below.
		Six Months Ended June 30, 2014			Six Months Ended June 30, 2013
	Risk-free interest rate		1.70-1.77	%		0.65-1.42	%
	Volatility		69.15-70.93	%		33.35-45.76	%
	Term (in years)		5-6.25			5-6.25
	Dividend yield		0	%		0	%
Schedule of option activity	'
	A summary of activity under the LTIP and 2012 SOP and related information follows:
		Number of Shares Underlying Stock Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
	Balance at December 31, 2013		15,632,742		$	1.44			7.2	$	58,878,132
	Granted		1,625,000		$	4.82			9.7	$	162,000
	Exercised		(728,844	)
	Expired		—
	Cancelled		(5,770	)
	Balance at June 30, 2014		16,523,128		$	1.82			7.3	$	43,880,788
	Vested and Exercisable at June 30, 2014		11,958,967		$	1.17			6.1	$	38,859,553

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Tables	'
Schedule of future minimum rental payments	'
	As of June 30, 2014, future minimum rental payments are as follows:
	Years Ending
	December 31,
	2014 (6 months)	$	182,877
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,748
	Total minimum lease payments	$	1,633,090

INVENTORY_Details

INVENTORY (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory	'	'
Finished product	$747,001	$621,679
Raw material	518,701	250,943
Deferred costs	187,292	170,996
Inventory	$1,452,994	$1,043,618

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Current Assets	'	'
Prepaid research and development costs	$1,663,147	$1,267,588
Prepaid consulting	514,596	530,596
Other receivables-related party (Note 14)	249,981	249,981
Prepaid insurance	174,917	125,266
Other prepaid costs	75,559	44,262
Deferred financing costs	'	260,022
TOTAL OTHER CURRENT ASSETS	$2,678,200	$2,477,715

FIXED_ASSETS_Details_Narrative

FIXED ASSETS (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation Expense	$8,469	$7,381	$15,591	$12,084

FIXED_ASSETS_Details

FIXED ASSETS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fixed assets, gross	$186,045	$155,083
Accumulated depreciation	-109,356	-93,765
Fixed Assets, net	76,689	61,318
Equipment (Member)	'	'
Fixed assets, gross	132,150	108,458
Furniture and Fixtures (Member)	'	'
Fixed assets, gross	$53,895	$46,625

PREPAID_EXPENSE_Details

PREPAID EXPENSE (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Assets	'	'
Prepaid research and development costs	$566,923	$824,221
Prepaid manufacturing costs	899,000	899,000
Accreted prepaid costs	45,626	27,234
TOTAL PREPAID EXPENSE	$1,511,549	$1,750,455

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Amortization expense	$5,625	$3,255	$11,570	$6,509
OPERA software patent (Member)	'	'	'	'
Amortization period	'	'	'20 years	'
Hormone therapy drug candidate patents (Member)	'	'	'	'
Amortization period	'	'	'20 years	'
Development costs for corporate website (Member)	'	'	'	'
Amortization period	'	'	'36 months	'

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details ) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Finite-Lived Intangible Assets	'	'	'
Accumulated Amortization	($101,730)	'	($90,160)
Indefinite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	'	'	755,748
Net Amount	'	'	665,588
Gross Carrying Amount	968,837	'	755,748
Net Amount	867,107	'	665,588
Hormone therapy drug candidate patents (Member)	'	'	'
Finite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	387,806	'	'
Accumulated Amortization	-8,489	'	'
Net Amount	379,317	'	'
Indefinite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	381,369	'	572,726
Net Amount	381,369	'	572,726
Multiple trademarks for vitamins/supplements (Member)	'	'	'
Indefinite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	75,968	'	59,328
Net Amount	75,968	'	59,328
OPERA software patent (Member)	'	'	'
Finite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	31,951	'	31,951
Accumulated Amortization	-1,498	'	-499
Net Amount	30,453	'	31,452
Weighted Average Amortization Period	'15 years 3 months	'15 years 9 months 15 days	'
Development costs for corporate website (Member)	'	'	'
Finite-Lived Intangible Assets	'	'	'
Gross Carrying Amount	91,743	'	91,743
Accumulated Amortization	-91,743	'	-89,661
Net Amount	'	'	$2,082
Weighted Average Amortization Period	'	'4 months	'
Hormone therapy drug candidate patents (Member)	'	'	'
Finite-Lived Intangible Assets	'	'	'
Weighted Average Amortization Period	'18 years 9 months	'	'

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Estimated amortization expense for the year:	'
2014 (6 months)	$11,250
2015	22,500
2016	22,500
2017	22,500
2018	$22,500

OTHER_CURRENT_LIABILITIES_Deta

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'	'
Date dividend declared	'2010-06	'2010-06
Dividends Payable, amount per share	$0.40	$0.40
Unclaimed dividends	$41,359	$41,359

OTHER_CURRENT_LIABILITIES_Deta1

OTHER CURRENT LIABILITIES (Details) (USD $)	Jun. 30, 2014		Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'		'
Accrued payroll and commission costs	$1,207,486		$941,313
Accrued clinical trial costs	725,723		129,208
Accrued vacation costs	406,597		256,920
Allowance for wholesale distributor fees	273,026		306,303
Accrued legal and accounting expense	192,972		224,550
Accrued royalties	155,221		52,188
Allowance for coupons and returns	107,007		126,233
Accrued rent	94,435		'
Other accrued expenses	166,951	[1]	177,900	[1]
Accrued financing costs	'		850,000
Accrued lab research	'		536,574
TOTAL OTHER CURRENT LIABILITIES	$3,329,418		$3,601,189
[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our common stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2014 and December 31, 2013.

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (Multiple Advance Revolving Credit Note (Plato Warrant) (Member), USD $)	0 Months Ended
	Mar. 21, 2013	Mar. 13, 2013	Feb. 25, 2013	Jan. 31, 2013
Multiple Advance Revolving Credit Note (Plato Warrant) (Member)	'	'	'	'
Maximum principal amount	'	'	'	$10,000,000
Stated interest rate	'	'	'	6.00%
Description of interest payment	'	'	'	'Interest payments were due and payable on the tenth day following the end of each calendar quarter
Proceeds from revolving credit note	'	200,000	200,000	'
Repayment of revolving credit note	$401,085	'	'	'
Number of shares purchased	'	'	'	1,250,000
Exercise price of warrants	'	'	'	$3.20

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Anti-dilutive shares excluded from earnings per share calculation	30,645,255	28,949,292
Stock Option [Member]	'	'
Anti-dilutive shares excluded from earnings per share calculation	16,523,128	14,655,793
Warrant [Member]	'	'
Anti-dilutive shares excluded from earnings per share calculation	14,122,127	14,293,499

STOCKHOLDERS_EQUITY_Details_Na

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	6 Months Ended			0 Months Ended		6 Months Ended	0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Apr. 20, 2013	Mar. 20, 2013	Jun. 30, 2014	Sep. 25, 2013
				Jefferies LLC (Underwriters) (Member)	Jefferies LLC (Underwriters) (Member)	Jefferies LLC (Underwriters) (Member)	Stifel, Nicolaus & Company - Underwriters (Member)
Common stock, par value	$0.00	'	$0.00	'	'	'	'
Common stock, shares authorized	250,000,000	'	250,000,000	'	'	'	'
Common stock, shares issued	145,926,973	'	144,976,757	'	'	'	'
Common stock, shares outstanding	145,926,973	'	144,976,757	'	'	'	'
Value of shares issued in exercise of stock options	$287,288	$31,000	'	'	'	'	'
Number of shares issued in exercise of stock options	728,844	75,423	'	'	'	'	'
Options exercised for cash	615,007	'	'	'	'	'	'
Options exercised under cashless exercise	119,607	'	'	'	'	'	'
Shares issued under cashless exercise of options	113,837	'	'	'	'	'	'
Options Granted	50,000	'	'	'	'	'	'
Number of shares issued in exercise of warrants	171,372	'	'	'	'	'	'
Value of shares issued in exercise of warrants	87,000	'	'	'	'	'	'
Number of shares issued during the period	'	'	'	'	'	29,411,765	13,750,000
Share price (in dollars per share)	'	'	'	'	$1.70	'	$2.40
Share price to underwritters (in dollars per share)	'	'	'	'	$1.58	'	$2.23
Value of shares issued during the period	'	'	'	'	'	45,400,000	30,200,000
Additional period to purchase shares via option	'	'	'	'	'	'30 days	'
Total Additional common stock issued under shelf registration statement	'	'	'	'	4,411,765	'	'
Additional common stock issued under shelf registration statement	'	'	'	1,954,587	'	'	'
Additional common stock issued under shelf registration statement,value	'	'	'	$3,100,000	'	'	'

STOCKHOLDERS_EQUITY_Details_Na1

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

31-May-13

Jun. 30, 2013

11-May-13

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Sancilio and Company Warrants (Member)

Sancilio & Company Warrants 1st Installments (Member)

Sancilio & Company Warrants 1st Installments (Member)

Sancilio and Company Warrants 2nd Installments (Member)

Sancilio and Company Warrants 2nd Installments (Member)

Sancilio and Company Warrants 2nd Installments (Member)

Sancilio and Company Warrants 3rd Installments (Member)

Multiple Advance Revolving Credit Note (Plato Warrant) (Member)

Minimum (Member)

Maximum (Member)

Warrants:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

$14,122,127

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average contractual remaining life

'

'3 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price

'

1.8

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per share)

'

'

'

'

$2.01

'

'

'

'

'

'

$3.20

$0.24

$3.20

Number of shares issuable for warrants granted

'

'

'

'

850,000

'

283,333

283,333

'

'

283,334

1,250,000

'

'

Expiration date of warrants

'

'

'

'

'

'

'

'

'

'

'

31-Jan-19

'

'

Vesting date of warrants

'

'

'

'

'

'

30-Jun-13

'

'

'

'

31-Oct-13

'

'

Fair value of warrants

'

'

'

'

'

405,066

'

462,196

'

'

'

1,711,956

'

'

Expected term

'

'

'

'

'

'5 years

'

'5 years

'

'

'

'6 years

'

'

Volatility rate

'

'

'

'

'

1.12%

'

1.41%

'

'

'

44.29%

'

'

Risk free rate

'

'

'

'

'

45.89%

'

45.84%

'

'

'

0.88%

'

'

Dividend yield

'

'

'

'

'

0.00%

'

0.00%

'

'

'

0.00%

'

'

Financing costs

395,981

260,027

659,968

'

'

'

'

'

'

'

'

'

'

'

Number of shares issuable for warrants forfeited

'

'

'

'

833,000

'

'

'

'

'

'

'

'

'

Valuation method of warrants

'

'

'

'

'

'Black-Scholes Model

'

'

'

'

'

'

'

'

Non-cash compensation recongised

'

'

'

'

'

405,066

'

'

38,517

77,034

'

'

'

'

Prepaid expense-short term

'

'

'

'

'

'

'

'

154,068

154,068

'

'

'

'

Prepaid expense-long term

'

1,511,549

'

1,750,455

'

'

'

'

192,577

192,577

'

'

'

'

Unamortized warrant costs

'

$1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Details_Na2

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Options purchase Common Stock of the Company:	'	'	'	'	'
Weighted average issue date fair value	$2.99	'	$2.99	'	'
Unrecognized stock based compensation	$6,621,000	'	$6,621,000	'	'
Stock Options (Member)	'	'	'	'	'
Options purchase Common Stock of the Company:	'	'	'	'	'
Stock based compensation	1,250,002	561,810	2,070,385	1,161,770	'
Exercise prices of outstanding options -lower price	'	'	$0.10	'	'
Exercise prices of outstanding options -upper price	'	'	$5.21	'	'
Weighted average period of unrecognized stock based compensation	'	'	'2 years 1 month 6 days	'	'
2009 Long Term Incentive Compensation Plan (Member)	'	'	'	'	'
Options purchase Common Stock of the Company:	'	'	'	'	'
Description of plan	'	'	'To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.	'	'
Number of shares authorized for issuance	25,000,000	'	25,000,000	'	'
Numbers of options oustanding	14,554,654	'	14,554,654	'	'
2012 Stock Incentive Plan (Member)	'	'	'	'	'
Options purchase Common Stock of the Company:	'	'	'	'	'
Description of plan	'	'	'Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.	'	'
Number of shares authorized for issuance	10,000,000	'	10,000,000	'	'
Numbers of options oustanding	1,968,474	'	1,968,474	'	'
LTIP and 2012 SOP (Member)	'	'	'	'	'
Options purchase Common Stock of the Company:	'	'	'	'	'
Numbers of options oustanding	16,523,128	'	16,523,128	'	15,632,742
Stock based compensation	$38,084	$7,477	$223,726	$7,477	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (Stock Options (Member))	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Expected dividend yield	0.00%	0.00%
Minimum (Member)	'	'
Risk-free interest rate	1.70%	0.65%
Expected Volatility	69.15%	33.35%
Expected term	'5 years	'5 years
Maximum (Member)	'	'
Risk-free interest rate	1.77%	1.42%
Expected Volatility	70.93%	45.76%
Expected term	'6 years 3 months	'6 years 3 months

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Number Options	'	'	'
Options Granted	50,000	'	'
Options Exercised	728,844	75,423	'
Weighted Average Remaining Contractual Life	'	'	'
Options outstanding	'	'	'7 years 2 months 12 days
LTIP and 2012 SOP (Member)	'	'	'
Number Options	'	'	'
Options outstanding, beginning	15,632,742	'	'
Options Granted	1,625,000	'	'
Options Exercised	-728,844	'	'
Options Cancelled	-5,770	'	'
Options outstanding, ending	16,523,128	'	'
Vested and exercisable	11,958,967	'	'
Weighted Average Exercise Price	'	'	'
Options outstanding, beginning	1.44	'	'
Granted	482	'	'
Options outstanding, ending	1.82	'	'
Vested and exercisable	1.17	'	'
Weighted Average Remaining Contractual Life	'	'	'
Options outstanding	'7 years 3 months 18 days	'	'
Granted	'9 years 8 months 12 days	'	'
Vested and exercisable	'6 years 1 month 6 days	'	'
Aggregate Intrinsic Value	'	'	'
Options outstanding, beginning	58,878,132	'	'
Granted	162,000	'	'
Options outstanding, ending	43,880,788	'	'
Vested and exercisable	38,859,553	'	'

RELATED_PARTIES_Details_Narrat

RELATED PARTIES (Details Narrative) (Pernix Therapeutics LLC (Member), USD $)	Jun. 30, 2014	Dec. 31, 2013
Pernix Therapeutics LLC (Member)	'	'
Receivables- legal fee reimbursement	$249,981	$249,981
Payable - related party	$46,000	$46,000

BUSINESS_CONCENTRATIONS_Detail

BUSINESS CONCENTRATIONS (Details Narrative)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Supplier Concentration Risk (Member)	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk	71.00%	98.00%
Revenue - Prescription dietary (Member)	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk	97.17%	98.16%
Recognized Revenue (Member)	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk	81.65%	74.08%
Deferred revenue (Member)	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk	95.20%	97.94%

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Non-cancelable operating lease term	'	'63 months	'	'
Monthly Base rent of leases	'	$30,149	'	'
Future minimum lease payments	1,899,414	1,899,414	'	1,633,090
Rental Expense	90,448	180,896	60,168	'
Rental income	'	$35,960	'	'

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Future minimum rental payments, year ending December 31,	'	'
2014	'	$182,877
2015	'	371,240
2016	'	382,377
2017	'	393,848
2018	'	302,748
Total minimum lease payments	$1,899,414	$1,633,090

SUBSEQUENT_EVENTS_Details_Narr

SUBSEQUENT EVENTS (Details Narrative) (USD $)	6 Months Ended		0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jul. 29, 2014	Jul. 29, 2014
			Subsequent Event [Member]	Subsequent Event [Member]
				Goldman Sachs (Underwriter) [Member]
Number of shares issued during the period	'	'	8,565,310	'
Share price (in dollars per share)	'	'	$4.67	'
Share price to underwritters (in dollars per share)	'	'	'	$4.37
Value of shares issued during period	'	'	$37,200,000	'
Total Additional common stock issued under shelf registration statement	'	'	'	1,284,796
Value of shares issued in exercise of stock options	$287,288	$31,000	'	$5,600,000
Number of shares issued in exercise of stock options	728,844	75,423	'	1,284,796